About Us
Rappta Therapeutics is a late pre-clincal stage biopharmaceutical company
We are working on a first-in-class series of anti-cancer molecular glues that reactivate a key tumor suppressor, protein phosphatase 2A (PP2A). Rappta’s proprietary tools and understanding of the target allow us to therapeutically reactivate PP2A, a critical enzyme regulating protein de-phosphorylation and tumor growth. As a result of PP2A’s central role in the regulation of protein phosphorylation, Rappta’s PP2A-reactivating technologies have platform potential for treating a broad range of human diseases.
What is PP2A
PP2A has a central role in human biology
The hyperphosphorylation of proteins because of the activation of kinases and inactivation of phosphatases is a hallmark of many diseases ranging from neurodegeneration to cancer.
Our Technology
Our proprietary approach to activate PP2A
PP2A is a key tumor suppressor and a critical enzyme regulating protein de-phosphorylation and tumor growth, but it has to date been very difficult to target pharmaceutically.
Our team
An experienced team of biopharmaceutical leaders
We have assembled a strong scientific, medchem, management, and commercial team based in Finland and the US. Our scientific team has published seminal papers on the structural, functional, and biological mechanisms of PP2A inactivation in human cancer.
News & Articles
Rappta Therapeutics Appoints Sunjeet Sawhney as Chief Executive Officer
Rappta Therapeutics announces today the appointment of Sunjeet Sawhney as Chief Executive Officer (CEO) with immediate effect. Rappta’s Co-founder and Founding CEO Mikko Mannerkoski will move to be Chief Financial Officer (CFO) as planned.
